IPO
Vectura Group plc confirms its R&D investment priorities, announces a proposed £50 million capital return and provides an unaudited pre-close trading update.
A list of the top 10 biotech IPOs from January to the end of June this year shows significant involvement in the Hong Stock exchange, with five companies based in China, and one, Frontage Holdings, operating in both the U.S. and China.
Todos Medical Ltd., a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer’s disease, announced that it has launched a roadshow for a public offering of up to $7,000,000 of units.
RA Capital Management, LLC announced the first and final closing of its inaugural venture fund, RA Capital Nexus Fund, L.P., at just over $300 million, boosting RA Capital’s private deal capacity to nearly $1 billion and total assets under management to approximately $2.5 billion.
vasopharm GmbH, a private biopharmaceutical company developing a novel treatment for traumatic brain injury, announced the successful completion of a €9.5 million financing co-led by HeidelbergCapital Private Equity and EF Investments.
BioArctic received MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s disease
Allergy Therapeutics plc provides a trading update for the year ended 30 June 2019 ahead of its Preliminary Results to be announced on 25 September 2019.
Heidelberg Pharma AG published its financial report on the first six months of 2019
Expedeon AG announced that the Annual General Meeting held in Heidelberg yesterday, July 09, 2019, approved all management proposals.
Global, unaudited sales of HEMOBLAST™ Bellows for the first half of 2019 were €1.4 million – on track to achieve 2019 revenue guidance range of €4.0-4.5 million; projection for 15% market share in the US and main European countries remains a long-term goal
PRESS RELEASES